CompletedNCT00645099

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Medication studyAges 18–65Multiple countries

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Buenos Aires and 45 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateOctober 2007

Recruitment status: Completed
Enrollment listed in the registry: 462
Sponsor: Janssen-Cilag International NV
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: France, Argentina, Egypt, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT00645099
Official title: Show the full official title
A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia

Completed

Buenos Aires, Argentina · Córdoba, Argentina · Mendoza, Argentina

44 more locations

FAQ

Who is behind this study?

The study sponsor is Janssen-Cilag International NV.

Did this study involve medication?

Yes. The study involved medication, including olanzapine and paliperidone ER.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.